Meningioma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Meningioma – Pipeline Review, H2 2017’, provides an overview of the Meningioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Meningioma

The report reviews pipeline therapeutics for Meningioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Meningioma therapeutics and enlists all their major and minor projects

The report assesses Meningioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Meningioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Meningioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Meningioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Eli Lilly and Co

Genentech Inc

GlaxoSmithKline Plc

Merck & Co Inc

Merck KGaA

Novartis AG

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Progenics Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Meningioma - Overview 7

Meningioma - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Meningioma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Meningioma - Companies Involved in Therapeutics Development 21

Arno Therapeutics Inc 21

AstraZeneca Plc 21

Boehringer Ingelheim GmbH 22

Eli Lilly and Co 22

Genentech Inc 22

GlaxoSmithKline Plc 23

Merck & Co Inc 23

Merck KGaA 24

Novartis AG 24

Ono Pharmaceutical Co Ltd 25

Pharma Mar SA 25

Progenics Pharmaceuticals Inc 26

Meningioma - Drug Profiles 27

abemaciclib - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

afatinib dimaleate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AR-42 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

avelumab - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Edotreotide Labeled Yttrium 90 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

GSK-2256098 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

HXR-9 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

nitrosylcobalamin - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

nivolumab - Drug Profile 73

R&D Progress 74

pasireotide ER - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

pembrolizumab - Drug Profile 129

R&D Progress 130

selumetinib sulfate - Drug Profile 198

Product Description 198

Mechanism Of Action 198

R&D Progress 198

trabectedin - Drug Profile 206

Product Description 206

Mechanism Of Action 206

R&D Progress 206

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile 214

Product Description 214

Mechanism Of Action 214

R&D Progress 214

vismodegib - Drug Profile 215

Product Description 215

Mechanism Of Action 215

R&D Progress 215

vistusertib - Drug Profile 221

Product Description 221

Mechanism Of Action 221

R&D Progress 221

Meningioma - Dormant Projects 224

Meningioma - Discontinued Products 225

Meningioma - Product Development Milestones 226

Featured News & Press Releases 226

Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma 226

Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe 226

Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors 227

Appendix 228

Methodology 228

Coverage 228

Secondary Research 228

Primary Research 228

Expert Panel Validation 228

Contact Us 228

Disclaimer 229

List of Tables

List of Tables

Number of Products under Development for Meningioma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products under Development by Universities/Institutes, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Universities/Institutes, H2 2017 12

Number of Products by Stage and Target, H2 2017 14

Number of Products by Stage and Mechanism of Action, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Meningioma – Pipeline by Arno Therapeutics Inc, H2 2017 21

Meningioma – Pipeline by AstraZeneca Plc, H2 2017 21

Meningioma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 22

Meningioma – Pipeline by Eli Lilly and Co, H2 2017 22

Meningioma – Pipeline by Genentech Inc, H2 2017 23

Meningioma – Pipeline by GlaxoSmithKline Plc, H2 2017 23

Meningioma – Pipeline by Merck & Co Inc, H2 2017 24

Meningioma – Pipeline by Merck KGaA, H2 2017 24

Meningioma – Pipeline by Novartis AG, H2 2017 25

Meningioma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 25

Meningioma – Pipeline by Pharma Mar SA, H2 2017 26

Meningioma – Pipeline by Progenics Pharmaceuticals Inc, H2 2017 26

Meningioma – Dormant Projects, H2 2017 224

Meningioma – Discontinued Products, H2 2017 225

List of Figures

List of Figures

Number of Products under Development for Meningioma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 13

Number of Products by Stage and Top 10 Targets, H2 2017 13

Number of Products by Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports